InnaVirVax strenghtens patent protection of VAC-3S immunotherapy

20-06-2012: InnaVirVax announced that a new European patent application has been filed on VAC-3S, a immunotherapy for the treatment of HIV infections.

This patent application claims the use of new immunogenic compositions that are optimized to induce a strong immune response in humans. It also relates to use of such immune compositions with enhanced properties compared to references. This industrial property consolidation is based on the research undertaken by the Company since its inception, more than 3 years ago. It deals with an essential stake showing InnaVirVax’s ability to create value through innovation and patents.

InnaVirVax is developing VAC-3S from a patent family covering Europe, the United States, Canada and China whose property belongs to Inserm and the AP-HP. InnaVirVax has been granted an exclusive worldwide license since May 2009.

This immunotherapy is currently under phase I/IIa clinical development. The clinical trial is being conducted since February 2012 in two major clinical reference centers in Paris: the Pitié-Salpêtrière and Cochin Hospitals. It involves 24 patients infected with HIV-1 whose viral load is controlled under antiretroviral therapy.